Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy
<p> V.N. Kuzmin </p> <p> A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation </p> <p> <b>Aim: </b>to assess the efficacy and safety of Ecofucin<sup>®</sup> in patients after performing planned gyneco...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LCC «Medicine-Inform»
2022-12-01
|
| Series: | РМЖ. Мать и дитя |
| Online Access: | http://wchjournal.com/upload/iblock/0ac/itxsl5r3xuwm0jvwc1ahykswd1awm9q1.pdf |
| _version_ | 1797294923450417152 |
|---|---|
| author | V.N. Kuzmin |
| author_facet | V.N. Kuzmin |
| author_sort | V.N. Kuzmin |
| collection | DOAJ |
| description | <p>
V.N. Kuzmin
</p>
<p>
A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
</p>
<p>
<b>Aim: </b>to assess the efficacy and safety of Ecofucin<sup>®</sup> in patients after performing planned gynecologic surgery procedures based on the changes in vaginal microbiota over time amid the use of systemic antimicrobial therapy (AMT).
</p>
<p>
<b>Patients and Methods: </b>this prospective open randomized comparative parallel-group clinical study involved patients without signs of vaginal microbiota dysbiosis — bacterial vaginosis or candidiasis, who were hospitalized for planned surgery procedures. The group 1 patients (n=39) received systemic AMT and Ecofucin<sup>®</sup> for intravaginal application once a day at the bedtime for 12 days, starting 6 days before the planned surgery and AMT initiation, while the group 2 patients (n=40) received only systemic AMT. The efficacy was assessed a day after the completion of AMT and the use of the tested medication (i.e. on day 13 after the initiation of Ecofucin application) and 30±2 days after the initiation of using the tested drug. Clinical, microbiological and molecular genetic methods were used for the assessment.
</p>
<p>
<b>Results: </b>symptoms common for vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis were reported by 18% and 21% of the group 2 patients at days 13 and 30±2 after the initiation of AMT, while such symptoms were not recorded in any of the group 1 patients (F=0,107, р=0,007). In 100% of the group 1 patients both lactobacilli and bifidobacteria were detected at all endpoints. In group 2, lactobacilli were found at days 13 and 30±2 in 93.8% and 97% of patients, respectively (F=0.035, p=0.2; F=0.017, p=0.458), bifidobacteria — in 84.4% and 81.1% of patients, respectively (F=0.092, р=0.016; F=0.107, р=0,007, respectively). At the baseline, the groups had similar results of the vaginal discharge culture tests. In the group 1 patients, Candida spp. were not identified at any of the endpoints, in group 2 — Candida spp. were found in 22.5% of patients, starting from day 13 (F=0,125, р=0,002). No adverse events were reported.
</p>
<p>
<b>Conclusion: </b>the administration of Ecofucin<sup>®</sup> vaginal suppositories containing natamycin 100 mg and excipient lactulose is effective for preventing microbiota dysbiosis — bacterial vaginosis and candidiasis in patients receiving antimicrobial therapy.
</p>
<p>
<b>Keywords: </b>vagina, microbiocenosis, antimicrobial therapy, lactobacilli, bifidobacteria, candidiasis, natamycin, lactulose.
</p>
<p>
<b>For citation:</b> Kuzmin V.N. Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy. Russian Journal of Woman and Child Health. 2022;5(4):292–296 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-292-296.
</p>
<br> |
| first_indexed | 2024-03-07T21:38:18Z |
| format | Article |
| id | doaj.art-2d243f256ec840b991452766ee600874 |
| institution | Directory Open Access Journal |
| issn | 2618-8430 2686-7184 |
| language | Russian |
| last_indexed | 2024-03-07T21:38:18Z |
| publishDate | 2022-12-01 |
| publisher | LCC «Medicine-Inform» |
| record_format | Article |
| series | РМЖ. Мать и дитя |
| spelling | doaj.art-2d243f256ec840b991452766ee6008742024-02-26T10:13:33ZrusLCC «Medicine-Inform»РМЖ. Мать и дитя2618-84302686-71842022-12-015433671Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapyV.N. Kuzmin0Russian Journal of Woman and Child Health, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> V.N. Kuzmin </p> <p> A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation </p> <p> <b>Aim: </b>to assess the efficacy and safety of Ecofucin<sup>®</sup> in patients after performing planned gynecologic surgery procedures based on the changes in vaginal microbiota over time amid the use of systemic antimicrobial therapy (AMT). </p> <p> <b>Patients and Methods: </b>this prospective open randomized comparative parallel-group clinical study involved patients without signs of vaginal microbiota dysbiosis — bacterial vaginosis or candidiasis, who were hospitalized for planned surgery procedures. The group 1 patients (n=39) received systemic AMT and Ecofucin<sup>®</sup> for intravaginal application once a day at the bedtime for 12 days, starting 6 days before the planned surgery and AMT initiation, while the group 2 patients (n=40) received only systemic AMT. The efficacy was assessed a day after the completion of AMT and the use of the tested medication (i.e. on day 13 after the initiation of Ecofucin application) and 30±2 days after the initiation of using the tested drug. Clinical, microbiological and molecular genetic methods were used for the assessment. </p> <p> <b>Results: </b>symptoms common for vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis were reported by 18% and 21% of the group 2 patients at days 13 and 30±2 after the initiation of AMT, while such symptoms were not recorded in any of the group 1 patients (F=0,107, р=0,007). In 100% of the group 1 patients both lactobacilli and bifidobacteria were detected at all endpoints. In group 2, lactobacilli were found at days 13 and 30±2 in 93.8% and 97% of patients, respectively (F=0.035, p=0.2; F=0.017, p=0.458), bifidobacteria — in 84.4% and 81.1% of patients, respectively (F=0.092, р=0.016; F=0.107, р=0,007, respectively). At the baseline, the groups had similar results of the vaginal discharge culture tests. In the group 1 patients, Candida spp. were not identified at any of the endpoints, in group 2 — Candida spp. were found in 22.5% of patients, starting from day 13 (F=0,125, р=0,002). No adverse events were reported. </p> <p> <b>Conclusion: </b>the administration of Ecofucin<sup>®</sup> vaginal suppositories containing natamycin 100 mg and excipient lactulose is effective for preventing microbiota dysbiosis — bacterial vaginosis and candidiasis in patients receiving antimicrobial therapy. </p> <p> <b>Keywords: </b>vagina, microbiocenosis, antimicrobial therapy, lactobacilli, bifidobacteria, candidiasis, natamycin, lactulose. </p> <p> <b>For citation:</b> Kuzmin V.N. Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy. Russian Journal of Woman and Child Health. 2022;5(4):292–296 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-292-296. </p> <br>http://wchjournal.com/upload/iblock/0ac/itxsl5r3xuwm0jvwc1ahykswd1awm9q1.pdf |
| spellingShingle | V.N. Kuzmin Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy РМЖ. Мать и дитя |
| title | Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| title_full | Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| title_fullStr | Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| title_full_unstemmed | Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| title_short | Ecofucin® for the prevention of vaginal microbiota dysbiosis — bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| title_sort | ecofucin r for the prevention of vaginal microbiota dysbiosis bacterial vaginosis and candidiasis amid the use of systemic antimicrobial therapy |
| url | http://wchjournal.com/upload/iblock/0ac/itxsl5r3xuwm0jvwc1ahykswd1awm9q1.pdf |
| work_keys_str_mv | AT vnkuzmin ecofucinforthepreventionofvaginalmicrobiotadysbiosisbacterialvaginosisandcandidiasisamidtheuseofsystemicantimicrobialtherapy |